{
    "nct_id": "NCT04509700",
    "official_title": "A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)",
    "inclusion_criteria": "* Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of parsaclisib.\n* Currently tolerating treatment in the parent Protocol.\n* Currently receiving clinical benefit from treatment with parsaclisib as monotherapy or in combination therapy with Itacitinib, ruxolitinib, or ibrutinib as determined by the investigator.\n* Has at least stable disease, as determined by the investigator.\n* Has demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.\n* Willingness and ability to comply with scheduled visits, treatment plans, including PJP prophylaxis, and any other study procedures indicated in this Protocol.\n* Willingness to avoid pregnancy or fathering children\n* Ability to comprehend and willingness to sign an ICF\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has been permanently discontinued from study treatment in the parent Protocol for any reason.\n* Able to access parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib therapy outside a clinical study.\n* Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.\n* Pregnant or breastfeeding women.",
    "miscellaneous_criteria": ""
}